UK markets open in 4 hours 43 minutes

Medios AG (0QB4.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
28.85-0.75 (-2.55%)
At close: 04:45PM BST
Full screen
Previous close29.60
Open28.85
Bid0.00 x 0
Ask0.00 x 0
Day's range27.95 - 28.90
52-week range27.95 - 28.90
Volume281
Avg. volumeN/A
Market cap4.189M
Beta (5Y monthly)1.32
PE ratio (TTM)0.64
EPS (TTM)0.45
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Medios AG: Contract of CEO Matthias Gaertner extended ahead of schedule

    DGAP-News: Medios AG / Key word(s): Contract/PersonnelMedios AG: Contract of CEO Matthias Gaertner extended ahead of schedule 01.08.2022 / 10:45 The issuer is solely responsible for the content of this announcement.Press releaseMedios AG: Contract of CEO Matthias Gaertner extended ahead of scheduleBerlin, August 01, 2022 – The Supervisory Board of Medios AG ("Medios") and the Chief Executive Officer (CEO) Matthias Gaertner have agreed to extend the existing Executive Board contract prematurely u

  • EQS Group

    Medios AG successfully holds Annual General Meeting 2022

    DGAP-News: Medios AG / Key word(s): AGM/EGM/Miscellaneous Medios AG successfully holds Annual General Meeting 2022 21.06.2022 / 14:38 The issuer is solely responsible for the content of this announcement.Press ReleaseMedios AG successfully holds Annual General Meeting 2022 Modernization of the Company's Articles of Association approved Compensation report approved New Stock Option Plan 2022 adoptedBerlin, June 21, 2022 – Medios AG (“Medios”), the leading provider of Specialty Pharma Solutions in

  • EQS Group

    Medios AG: Revenue and earnings at record levels in the first quarter

    DGAP-News: Medios AG / Key word(s): Quarterly / Interim Statement/Quarter ResultsMedios AG: Revenue and earnings at record levels in the first quarter 11.05.2022 / 07:32 The issuer is solely responsible for the content of this announcement.Press ReleaseMedios AG: Revenue and earnings at record levels in the first quarter Double-digit revenue growth and disproportionately high EBITDA pre1 increase Acquisition of NewCo Pharma Group: Significant strengthening of market position in manufacturing Out